Philippe Pouletty hands over to Professor Gérard Tobelem (a former President of EFS, the French national blood transfusion service) as President of the Board.
Pierre Morgon and Jean-Paul Prieels appointed as Board Members.
Theradiag (the theranostics and in vitro diagnostics company focused on autoimmune disease) today announced the appointment of Professor Gérard Tobelem as the new Chairman of the Board of Directors and the arrival of Pierre Morgon and Jean-Paul Prieels as new Board members. This reinforcement of the Board comes after the company’s name change (formerly bmd) and heralds its new strategy for developing and marketing theranostics for biologic therapies.
The former Head of the Hematology Department at Lariboisière Hospital (Paris) Professor Gérard Tobelem has been appointed as the President of Theradiag’s Board of Directors. He is an Officer of the French Legion of Honor, a Knight of the French Order of Merit and the winner of the 2006 Diderot Innovation Prize. Gérard Tobelem held a number of senior positions at the French Ministry of Research and Higher Education from 1993 to 1997 and served as Chief Executive of the French national blood transfusion service (Etablissement Français du Sang) from April 2009 to April 2012. He has also worked as a consultant for the R&D divisions of multinational pharmaceutical companies for several years.
“We are delighted to welcome Gérard Tobelem to the Board of Directors. His appointment as Chairman fits perfectly with the new strategy being driven forward by the Board. His scientific, medical and international expertise will significantly boost our development of novel, innovative products» emphasized former Chairman Philippe Pouletty, MD (CEO of Truffle Capital, Theradiag’s majority shareholder).
Professor Tobelem stated : “When a drug is put on the market, we already have statistical information about its efficacy and side effects on the population scale. However, when that same drug is prescribed to a patient, its efficacy and safety also depend on individual factors. Theradiag is able to provide novel, high-performance tools for better drug prescription and better patient monitoring.”
The Board of Directors also welcomes Jean-Paul Prieels as a new member. As a graduate in Biochemistry from the University of Brussels, Jean-Paul Prieels pursued a brilliant career in GlaxoSmithKline Biologicals’ R&D Division from 1987 until 2011, leaving the company as Senior Vice President, Research & Development.
Pharmaceutical industry expert, Pierre Morgon also joins the Board of Directors. As a Doctor of Pharmacy and an MBA holder with additional qualifications in Business Law, he has over 26 years of experience in both major pharma companies (such as Sanofi Pasteur, where he currently serves as Vice President Franchise & Global Marketing Strategy) and biotech firms (such as BioAlliance Pharma).
Philippe Pouletty MD served as Theradiag’s CEO and then Chairman of the Board since 2009. He was notably responsible for restructuring the company. Philippe Pouletty remains on the Board and will continue to bring his major contribution to the company’s strategy.
“We are delighted to welcome Jean-Paul Prieels and Pierre Morgon to the Board. Jean-Paul’s substantial clinical experience as well as scientific knowledge will be valuable assets for the company’s development”, commented Michel Finance, Theradiag CEO and Board Member. “Pierre’s international experience and knowledge of marketing, management and corporate strategy will be just as valuable”, he added.
Board member Gérard Vaillant (former Chairman of Johnson & Johnson’s Diagnostic Division and current CEO of Tecan) will also continue to provide Theradiag with the benefit of his significant international management experience.
Theradiag’s new Board of Directors now comprises:
Chairman of the Board: Gérard Tobelem
Board Members: Michel Finance, Pierre Morgon, Philippe Pouletty, Jean-Paul Prieels and Gérard Vaillant